L. Ciuffreda

发表

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

R. Foà, S. Chiaretti, G. Zupi, 2009, Neoplasia.

Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.

L. Ciuffreda, I. Falcone, C. Bazzichetto, 2020, Advances in experimental medicine and biology.

Role of mTOR Signaling in Tumor Microenvironment: An Overview

M. Milella, L. Ciuffreda, F. Cognetti, 2018, International journal of molecular sciences.

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

D. Trisciuoglio, G. Zupi, M. Milella, 2006, Cancer research.

PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition

S. Shirasawa, M. Milella, L. Ciuffreda, 2022, Frontiers in Oncology.

Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments

J. McCubrey, M. Milella, L. Ciuffreda, 2009 .

Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.

M. Fassan, A. Scarpa, G. Tortora, 2014, Current pharmaceutical design.

Optimizing the Illumina COVIDSeq laboratorial and bioinformatics pipeline on thousands of samples for SARS-CoV-2 Variants of Concern tracking

G. Ciliberto, G. Blandino, Carla Mottini, 2022, Computational and Structural Biotechnology Journal.

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration

G. Ciliberto, F. Cappuzzo, G. Sanguineti, 2022, International journal of molecular sciences.

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

E. Pescarmona, S. Rodig, M. Fanciulli, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

PTEN: Multiple Functions in Human Malignant Tumors

M. Milella, L. Ciuffreda, F. Cognetti, 2015, Front. Oncol..

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, Cancers.

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.

M. Filetti, G. Ciliberto, A. Vecchione, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma.

G. Ciliberto, P. Visca, E. Gallo, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy

M. Milella, L. Ciuffreda, E. Bria, 2010 .

Chapter 2 Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy

M. Milella, L. Ciuffreda, E. Bria, 2009 .

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

J. McCubrey, G. Tortora, F. Ciardiello, 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

A. Scarpa, C. Luchini, V. Corbo, 2020, Cells.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

A. Ceribelli, G. Tortora, M. Milella, 2013, Expert opinion on drug discovery.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine

G. Rossi, S. Novello, G. Tortora, 2013, Expert opinion on pharmacotherapy.

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around

A. Scarpa, V. Corbo, G. Tortora, 2019, Cancers.

Bcl‐2 overexpression in melanoma cells increases tumor progression‐associated properties and in vivo tumor growth

D. Ribatti, D. Trisciuoglio, G. Zupi, 2005, Journal of cellular physiology.

PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.

M. Milella, L. Ciuffreda, F. Cognetti, 2014, Advances in biological regulation.

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

M. Milella, L. Ciuffreda, F. Cognetti, 2018, Cancers.

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

G. Tortora, M. Pino, D. Melisi, 2011, Expert opinion on therapeutic targets.

Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer

G. Ciliberto, E. Gallo, B. Casini, 2020, Clinical and translational medicine.

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?

M. Fanciulli, M. Milella, L. Ciuffreda, 2019, Cancers.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

Stephen L. Abrams, A. Marchetti, R. Foà, 2012, Journal of Molecular Medicine.

The mTOR pathway: a new target in cancer therapy.

M. Milella, L. Ciuffreda, C. Di Sanza, 2010, Current cancer drug targets.

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Cancer drug resistance.

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

M. Filetti, G. Ciliberto, A. Vecchione, 2020, Journal for ImmunoTherapy of Cancer.

An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer

S. Novello, G. Tortora, M. Milella, 2015, Expert opinion on investigational drugs.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

A. Scarpa, V. Corbo, S. Shirasawa, 2018, Journal of experimental & clinical cancer research : CR.

KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy.

G. Ciliberto, F. Cappuzzo, A. Vecchione, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

Stephen L. Abrams, A. Marchetti, R. Foà, 2012, Journal of molecular medicine.

Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Journal of oncology.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

R. Maria, J. McCubrey, G. Blandino, 2012, Journal of Molecular Medicine.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

M. Todaro, G. Stassi, M. Konopleva, 2017, Scientific Reports.

Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells

D. Trisciuoglio, G. Zupi, M. Mottolese, 2004, Clinical Cancer Research.

Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities

F. Berrino, C. Campagnoli, P. Muti, 2017, Cell Discovery.